{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Study+Product&page=37", "query": { "intervention": "Control Study Product", "page": 37 }, "page_size": 10 }, "pagination": { "page": 37, "page_size": 10, "total_count": 4234, "total_pages": 424, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Study+Product&page=38&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Study+Product&page=36&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T01:13:57.760Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02431676", "title": "Survivorship Promotion In Reducing IGF-1 Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Prostate Cancer", "Lung Cancer", "Colon Cancer", "Melanoma of Skin", "Endometrial Cancer", "Liver Cancer", "Pancreatic Cancer", "Rectal Cancer", "Kidney Cancer", "Other Solid Malignant Tumors" ], "interventions": [ { "name": "Metformin", "type": "DRUG" }, { "name": "Coach Directed Behavioral Weight Loss", "type": "BEHAVIORAL" }, { "name": "Self-control weight loss", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 121, "start_date": "2015-05", "completion_date": "2018-12", "has_results": true, "last_update_posted_date": "2024-08-28", "last_synced_at": "2026-10-24T01:13:57.760Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02431676" }, { "nct_id": "NCT01834274", "title": "Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 Diabetes", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Fasiglifam (TAK-875)", "type": "DRUG" }, { "name": "Fasiglifam (TAK-875) Placebo", "type": "DRUG" }, { "name": "Sitagliptin", "type": "DRUG" }, { "name": "Sitagliptin Placebo", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 96, "start_date": "2013-06", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2015-09-28", "last_synced_at": "2026-10-24T01:13:57.760Z", "location_count": 44, "location_summary": "Huntsville, Alabama • Chandler, Arizona • Glendale, Arizona + 41 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01834274" }, { "nct_id": "NCT04286789", "title": "Randomized, Double-blind, Vehicle Controlled, Repeat Dose Comparative Study in RA Patients Managed With DMARDs", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Low dose ORTD-1", "type": "DRUG" }, { "name": "Low dose vehicle control", "type": "DRUG" }, { "name": "High dose ORTD-1", "type": "DRUG" }, { "name": "High dose vehicle control", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oryn Therapeutics, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2021-03-22", "completion_date": "2021-10-12", "has_results": false, "last_update_posted_date": "2021-10-19", "last_synced_at": "2026-10-24T01:13:57.760Z", "location_count": 3, "location_summary": "Los Angeles, California • Tustin, California • Miami, Florida", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Tustin", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04286789" }, { "nct_id": "NCT00768989", "title": "Phase IIB Pilot of Atazanavir + Raltegravir", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV" ], "interventions": [ { "name": "Atazanavir", "type": "DRUG" }, { "name": "Raltegravir", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Tenofovir/Emtricitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 167, "start_date": "2008-11", "completion_date": "2010-05", "has_results": true, "last_update_posted_date": "2012-02-24", "last_synced_at": "2026-10-24T01:13:57.760Z", "location_count": 9, "location_summary": "Phoenix, Arizona • New Haven, Connecticut • Washington D.C., District of Columbia + 5 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00768989" }, { "nct_id": "NCT00296491", "title": "Study Of Allergic Rhinitis In Patients Who Also Have Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "fluticasone propionate/salmeterol (FSC)", "type": "DRUG" }, { "name": "montelukast (MON)", "type": "DRUG" }, { "name": "fluticasone propionate (FP)", "type": "DRUG" }, { "name": "placebo nasal", "type": "DRUG" }, { "name": "ADVAIR DISKUS", "type": "DRUG" }, { "name": "placebo capsule", "type": "DRUG" }, { "name": "placebo DISKUS", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 725, "start_date": "2005-09", "completion_date": "2007-10", "has_results": true, "last_update_posted_date": "2016-12-16", "last_synced_at": "2026-10-24T01:13:57.760Z", "location_count": 104, "location_summary": "Birmingham, Alabama • Glendale, Arizona • Scottsdale, Arizona + 88 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00296491" }, { "nct_id": "NCT07599813", "title": "A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis", "Atopic", "Dermatitis", "Dermatitis, Atopic", "Dermatologic Disease", "Eczema", "Eczema Atopic Dermatitis", "Eczema, Atopic" ], "interventions": [ { "name": "Camoteskimab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Apollo Therapeutics Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 280, "start_date": "2026-05-28", "completion_date": "2028-04-30", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-10-24T01:13:57.760Z", "location_count": 33, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Bryant", "state": "Arkansas" }, { "city": "Huntington Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07599813" }, { "nct_id": "NCT01387230", "title": "Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "GSK573719", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 206, "start_date": "2011-07-01", "completion_date": "2012-02-13", "has_results": true, "last_update_posted_date": "2017-11-09", "last_synced_at": "2026-10-24T01:13:57.760Z", "location_count": 4, "location_summary": "Sunset, Louisiana • Easley, South Carolina • Spartanburg, South Carolina + 1 more", "locations": [ { "city": "Sunset", "state": "Louisiana" }, { "city": "Easley", "state": "South Carolina" }, { "city": "Spartanburg", "state": "South Carolina" }, { "city": "Union", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01387230" }, { "nct_id": "NCT01846481", "title": "A Randomized, 4-sequence, 2-period, Double-blind, Placebo Controlled Study With a DSM-IV-TR Diagnosis of Cocaine Abuse", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Opioid Dependence", "Opioid Related Disorders", "Cocaine Dependence" ], "interventions": [ { "name": "RBP-8000 100 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Cocaine", "type": "DRUG" }, { "name": "RBP-8000 200 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Indivior Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "21 Years to 50 Years" }, "enrollment_count": 40, "start_date": "2013-04", "completion_date": "2013-06", "has_results": false, "last_update_posted_date": "2016-09-23", "last_synced_at": "2026-10-24T01:13:57.760Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01846481" }, { "nct_id": "NCT07450430", "title": "Optimal Timing of Ketamine Initiation for SCD Pain", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Sickle Cell Disease", "Sickle Cell Crisis" ], "interventions": [ { "name": "Ketamine hydrochloride injection", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Boston Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "24 Years", "sex": "ALL", "summary": "6 Years to 24 Years" }, "enrollment_count": 90, "start_date": "2026-02", "completion_date": "2030-02", "has_results": false, "last_update_posted_date": "2026-03-09", "last_synced_at": "2026-10-24T01:13:57.760Z", "location_count": 1, "location_summary": "Brookline, Massachusetts", "locations": [ { "city": "Brookline", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07450430" }, { "nct_id": "NCT07799207", "title": "Effects of Continuous Yogurt Intake on Immunomodulatory Function and Subjective Health Status in Healthy U.S. Adults", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Immune Function" ], "interventions": [ { "name": "Yogurt drink", "type": "DIETARY_SUPPLEMENT" }, { "name": "Acidified lactic beverage", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "Meiji Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 118, "start_date": "2026-09-14", "completion_date": "2027-06-28", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-10-24T01:13:57.760Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07799207" } ] }